Accelerating Europe's Progress in CNS Gene Therapy
Navigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic
With systemic toxicity challenges plaguing the AAV field, low-dose CNS indications are an ideal target for gene therapy. The plethora of neurological indications dominating gene therapy pipelines vary from rare neurological disorders to more common diseases including Parkinson’s, epilepsy and neurodevelopmental disorders.
As programs advance globally, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the field’s definitive forum to showcase the European landscape’s progress and specific regulatory challenges. Gene therapy developers from all of the world, including Europe’s brightest minds in CNS gene therapy, will unite in Paris to share their research progress and host an industry-dedicated discussion.
View the world-class speaker faculty and topics for discussion here
Your Expert Speakers Include:
Maria Beatrice Panico
Leading Senior Medical Assessor, Clinical Investigations & Trials, Science, Research & Innovation Group
Medicines & Healthcare Products Regulatory Agency
Agenda Highlights Include:
- Utilizing NHPs and novel gene therapy tools to assess efficacy and biodistribution with different CNS administration routes
- Highlighting the specific needs of MHRA and EMA and the specific challenges of running trials to optimize your European strategy
- Optimizing preclinical model research with devices to improve CNS delivery translation into the clinic
- Hearing from neurosurgeons at the forefront of CNS gene therapy delivery to anticipate future scale up challenges
- Discussing the progress in brain targeting of technologies beyond AAV, and their ability to mitigate CNS toxicity
- Discussing novel vector research for improved selectivity and distribution to the CNS
- Evaluating the payer perspectives and addressing the commercial challenges of neurological gene therapies in Europe
- Addressing the bottleneck of NHP availability and CNS-specific CROs in Europe
Join over 100 fellow preclinical, translational, clinical and commercial gene therapy experts from European-based companies including AviadoBio, Orchard Therapeutics, UniQure, UCB, VectorY, Lysogene, AskBio Europe, Roche, Spark Therapeutics, Sanofi and Janssen for improved competitive intelligence of the new and established European companies leading the gene therapy field for neurological disorders.
Who Attended in 2021:
2022 Partners:
Other Events In The Gene Therapy Series:
